Heron Therapeutics Inc. Common Stock (HRTX)
Stock · NASDAQ · Health Care
$0.3668as of 10/16/2026
Price chart
Active signals
HRTX Signal Track Record
How signals performed across all stocks →What HRTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -1.2% | 39% | October 2, 2026 |
| Bollinger Band Breakdown | 21 | -6.7% | 43% | September 21, 2026 |
| Bollinger Band Breakout | 21 | 0.0% | 48% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -25.8% | 33% | May 5, 2026 |
| Any 20-session window (baseline) | -3.1% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HRTX
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granis…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 128
- Website
- www.herontx.com/
Fundamentals
- 1-day range
- $0.3601$0.4
- Market cap
- $94.45M
- P/E (trailing)
- —
- P/E (forward)
- -3.42
- EPS (trailing)
- $-0.19
- Dividend yield
- —
- Beta
- 1.65
- Avg. volume
- 2.43M
How Heron Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Heron Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- ONCYOncolytics Biotech Inc. Common Stock$0.5▼ 9.09%Market cap $95.55MP/E —$1.48$4.49
- ALDXAldeyra Therapeutics Inc. Common Stock$0.7▼ 5.02%Market cap $95.91MP/E —$0.8619$5.93
- RANIRani Therapeutics Holdings Inc. Class A Common Stock$0.641▼ 5.74%Market cap $96.76MP/E —$0.462$3.87
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.5 | ▼ 9.09% | $1.48$4.49 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $0.7 | ▼ 5.02% | $0.8619$5.93 |
| RANI Rani Therapeutics Holdings Inc. Class A Common Stock | $96.76M | — | $0.641 | ▼ 5.74% | $0.462$3.87 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- These stocks are moving in today's after hours sessionChartMill · 9/30/2026
- Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreementbenzinga · 9/29/2026
- Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License AgreementBenzinga · 9/29/2026
Insider Activity
Insider Actions →- Hensley Mark Earl · August 6, 2026 · Option Exercise31.3K
- Hensley Mark Earl · August 6, 2026 · Tax Withholding8.9K @ $0.5
- Hensley Mark Earl · July 31, 2026 · Option Exercise11.8K
- Duarte Ira · July 31, 2026 · Option Exercise11.7K
- Duarte Ira · July 31, 2026 · Tax Withholding3.3K @ $0.5
- Collard Craig A · July 31, 2026 · Option Exercise34.8K
- Forbes William P · July 31, 2026 · Option Exercise11.7K
- Forbes William P · July 31, 2026 · Tax Withholding3.3K @ $0.5
- Duarte Ira · July 30, 2026 · Option Exercise13.5K
- Duarte Ira · July 30, 2026 · Tax Withholding3.9K @ $0.5
- Collard Craig A · July 30, 2026 · Option Exercise50.0K
- Forbes William P · July 30, 2026 · Option Exercise11.8K
- Forbes William P · July 30, 2026 · Tax Withholding3.3K @ $0.5
- Duarte Ira · July 19, 2026 · Option Exercise3.9K
- Duarte Ira · July 19, 2026 · Tax Withholding1.1K @ $0.47
Institutional Ownership
March 31, 2026
- Total shares held
- 157.51M
- Total value held
- $125.50M
- Institutional holders
- 164
- Unknown30.05M
- Unknown12.24M
- Unknown10.11M
- Unknown9.82M
- Unknown8.75M
- Unknown7.81M
- Unknown7.63M
- Unknown6.34M
- Unknown6.25M
- Unknown6.14M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.